Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation

Finn Thorup Sellebjerg; M Krakauer; D Hesse; L P Ryder; I Alsing; P E H Jensen; Nils Koch-Henriksen; Anja Svejgaard; Per Soelberg Sørensen

doi:10.1111/j.1468-1331.2009.02716.x

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation

Finn Thorup Sellebjerg, M Krakauer, D Hesse, L P Ryder, I Alsing, P E H Jensen, Nils Koch-Henriksen, Anja Svejgaard, Per Soelberg Sørensen

54 Citations (Scopus)

Abstract

Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.

Original language	English
Journal	European Journal of Neurology
Volume	16
Issue number	12
Pages (from-to)	1291-8
Number of pages	8
ISSN	1351-5101
DOIs	https://doi.org/10.1111/j.1468-1331.2009.02716.x
Publication status	Published - 2009

Keywords

Antibodies, Neutralizing
Biological Markers
Chemokine CCL2
Chemokine CXCL10
Drug Resistance
Gene Expression
Gene Expression Profiling
Humans
Immunologic Factors
Interferon-beta
Membrane Proteins
Multiple Sclerosis
Oligonucleotide Array Sequence Analysis
Reverse Transcriptase Polymerase Chain Reaction

Access to Document

10.1111/j.1468-1331.2009.02716.x

Cite this

Sellebjerg, F. T., Krakauer, M., Hesse, D., Ryder, L. P., Alsing, I., Jensen, P. E. H., Koch-Henriksen, N., Svejgaard, A., & Sørensen, P. S. (2009). Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. European Journal of Neurology, 16(12), 1291-8. https://doi.org/10.1111/j.1468-1331.2009.02716.x

Sellebjerg, FT , Krakauer, M, Hesse, D, Ryder, LP, Alsing, I, Jensen, PEH, Koch-Henriksen, N, Svejgaard, A & Sørensen, PS 2009, 'Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation', European Journal of Neurology, vol. 16, no. 12, pp. 1291-8. https://doi.org/10.1111/j.1468-1331.2009.02716.x

@article{60c6deb7209140a09a2cb409fd649b3b,

title = "Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation",

abstract = "Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.",

keywords = "Antibodies, Neutralizing, Biological Markers, Chemokine CCL2, Chemokine CXCL10, Drug Resistance, Gene Expression, Gene Expression Profiling, Humans, Immunologic Factors, Interferon-beta, Membrane Proteins, Multiple Sclerosis, Oligonucleotide Array Sequence Analysis, Reverse Transcriptase Polymerase Chain Reaction",

author = "Sellebjerg, {Finn Thorup} and M Krakauer and D Hesse and Ryder, {L P} and I Alsing and Jensen, {P E H} and Nils Koch-Henriksen and Anja Svejgaard and S{\o}rensen, {Per Soelberg}",

year = "2009",

doi = "10.1111/j.1468-1331.2009.02716.x",

language = "English",

volume = "16",

pages = "1291--8",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation

AU - Sellebjerg, Finn Thorup

AU - Krakauer, M

AU - Hesse, D

AU - Ryder, L P

AU - Alsing, I

AU - Jensen, P E H

AU - Koch-Henriksen, Nils

AU - Svejgaard, Anja

AU - Sørensen, Per Soelberg

PY - 2009

Y1 - 2009

N2 - Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.

AB - Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.

KW - Antibodies, Neutralizing

KW - Biological Markers

KW - Chemokine CCL2

KW - Chemokine CXCL10

KW - Drug Resistance

KW - Gene Expression

KW - Gene Expression Profiling

KW - Humans

KW - Immunologic Factors

KW - Interferon-beta

KW - Membrane Proteins

KW - Multiple Sclerosis

KW - Oligonucleotide Array Sequence Analysis

KW - Reverse Transcriptase Polymerase Chain Reaction

U2 - 10.1111/j.1468-1331.2009.02716.x

DO - 10.1111/j.1468-1331.2009.02716.x

M3 - Journal article

C2 - 19558503

SN - 1351-5101

VL - 16

SP - 1291

EP - 1298

JO - European Journal of Neurology

JF - European Journal of Neurology

IS - 12

ER -

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation

Abstract

Keywords

Access to Document

Fingerprint

Cite this